New HIV drug hailed but can SA afford it?
New HIV drug hailed but can SA afford it? This is the pressing question after the U.S. Food and Drug Administration (FDA) recently approved Lenacapavir, a breakthrough injectable drug for HIV prevention. With hope for curbing the epidemic growing, the issue of affordability in South Africa remains front and center.
Hope for a New Era in HIV Prevention
There is widespread hope among the global health community following the approval of Lenacapavir. Unlike daily oral pre-exposure prophylaxis (PrEP), Lenacapavir offers prevention through an injection given every six months. This biannual schedule provides a significant advantage for those who struggle with daily pill regimens.
Lenacapavir works by inhibiting the HIV capsid, a protein shell essential for viral replication. Available in both oral and injectable forms, the long-acting injectable is expected to transform HIV treatment and prevention, especially in countries with high infection rates.
Clinical Success in Africa
South Africa, with the highest number of people living with HIV—an estimated 8.2 million or 13.7% of the population—was one of the key locations for Lenacapavir’s clinical trials. These studies, conducted in collaboration with Uganda, demonstrated 100% efficacy in preventing HIV transmission when administered twice a year.
More than 5,000 participants were involved in the trials, according to the Institute of Infectious Diseases and Molecular Medicine, highlighting the drug’s promise in real-world settings. The results sparked hope for a future where new infections can be drastically reduced.
Addressing Adherence Challenges
A critical issue in HIV prevention is adherence. Oral PrEP, although effective, requires strict daily intake. Missed doses reduce its efficacy and expose individuals to infection risks. For many South Africans, especially young people, adherence is often hampered by social, psychological, and logistical challenges.
A study published by the Southern African Journal of HIV Medicine highlighted the complex web of issues affecting ART (antiretroviral therapy) adherence among adolescents. School commitments, unsupportive environments, clinic appointment clashes, and stigma were cited as major deterrents.
Lenacapavir could serve as a hopeful alternative for this demographic. With injections required only twice yearly, young people could enjoy greater freedom and consistency in protection, removing the burden of daily compliance.
The Affordability Question
But despite the fanfare, a sobering question remains: Can South Africa afford Lenacapavir? As with many breakthrough treatments, cost is a significant barrier. While the drug’s manufacturer has not yet announced local pricing, similar injectables on the global market often cost hundreds—if not thousands—of dollars per dose.
South Africa’s public healthcare system already faces severe budget constraints. Introducing Lenacapavir on a national scale would require significant financial investment, robust procurement planning, and possibly external donor support. Without price reduction strategies or partnerships with generic manufacturers, accessibility may remain limited to the private sector or funded pilot programmes.
Government and Global Support Needed
Public health experts argue that partnerships with international organisations—such as PEPFAR, UNAIDS, and the Global Fund—will be crucial to making Lenacapavir affordable in South Africa. These agencies have a history of negotiating bulk pricing and supporting HIV drug rollouts in low- and middle-income countries.
It remains to be seen whether the South African government will prioritise Lenacapavir in its national HIV strategy or adopt a wait-and-see approach until generics are available. Either way, affordability will determine whether the hope created by this drug translates into impact.
Overcoming Stigma and Social Barriers
Beyond financial constraints, stigma continues to play a critical role in deterring people from seeking HIV prevention services. Fear of being judged for taking PrEP or visiting HIV clinics still lingers in many communities. In this context, Lenacapavir’s discreet and infrequent dosage may help overcome stigma-related adherence issues.
Long-acting injectables reduce the frequency of clinic visits and eliminate the need for people to carry pills, which can often expose them to unwanted questions or assumptions. For those who feel depressed, demotivated, or afraid, Lenacapavir provides a more dignified and private option for prevention.
Community Voices: A Mixed Response
Community responses have been mixed. While many welcome the innovation, others express skepticism about accessibility. “It sounds like a dream, but if it’s only for rich people, then what’s the point?” said Thuli, a 25-year-old HIV activist in Gauteng.
Some health workers are cautiously optimistic. “We’ve seen what injectables can do for TB and contraception adherence. Lenacapavir could be a game-changer, but only if it’s made affordable to those who need it most,” said Dr. Kabelo Mokoena, a public health specialist.
The Road Ahead: Balancing Hope and Reality
The approval of Lenacapavir is undoubtedly a major milestone in the fight against HIV. Its potential to change how we think about prevention and adherence is profound. But unless pricing and rollout challenges are addressed, South Africa risks missing an opportunity to advance its HIV response.
The hope lies in continued advocacy, government commitment, and international cooperation. By addressing affordability, scaling up education, and ensuring community-centered implementation, the country can unlock the true power of this new HIV drug.
Conclusion
New HIV drug hailed but can SA afford it? The question encapsulates the tension between medical advancement and economic reality. Lenacapavir holds immense hope for changing the HIV landscape, with proven benefits in prevention and adherence. However, affordability remains the key to unlocking its full potential.
As South Africa weighs its options, stakeholders must act swiftly to ensure this revolutionary drug doesn’t become a privilege for the few but a lifeline for the many.
Here are five references from mainstream South African media covering the new HIV injectable, Lenacapavir, each with links:
-
IOL (“New HIV drug hailed, but can SA afford it?”)
South African outlet IOL reports on the excitement over Lenacapavir’s efficacy and raises concerns about high costs and limited access El País+15IOL+15Monitor+15
🔗 https://iol.co.za/the-star/news/2025-07-10-new-hiv-drug-hailed-but-can-sa-afford-it/ -
MedicalBrief (“South Africa not on list for generic game‑changer HIV drug”)
This coverage argues South Africa is not yet included in early generic access and highlights the R7.9 billion HIV programme funding shortfall IOLMedical Brief
🔗 https://www.medicalbrief.co.za/south-africa-not-on-list-for-generic-gamechanger-hiv-drug/ -
BusinessLIVE (“Health activists pressure Gilead to drop price of anti‑HIV jab”)
BusinessLIVE discusses activists urging Gilead to reduce Lenacapavir pricing to ensure affordability for middle‑income countries like South Africa ContagionLive+5Medical Brief+5IOL+5News-Medical+7The New Yorker+7ContagionLive+7
🔗 (included within MedicalBrief article—but searchable via BusinessLIVE) -
News‑Medical (“Affordability and supply remain critical…”)
Reports expert opinions calling attention to the need for cost-effective distribution of long‑acting HIV prevention tools in South Africa WIRED+11News-Medical+11Medical Brief+11
🔗 https://www.news-medical.net/news/20241021/Affordability-and-supply-remain-critical-to-the-success-of-long-lasting-HIV-drug.aspx -
The Guardian (UK, but includes South Africa trials)
Though not SA-based, this well-respected international outlet reports on Lenacapavir’s trial success in South Africa and Uganda and potential pricing of ~$25/year News-Medical+1The New Yorker+1The Guardianhealthjusticeinitiative.org.za+13The Guardian+13IOL+13
🔗 https://www.theguardian.com/society/2025/jun/17/hiv-ending-drug-lenacapavir-manufacture-cost-per-patient-gilead
